Teruyoshi Yanaglta

Prof. Dr. Teruyoshi Yanaglta


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
XLXiaofang Liu
Xiaofang Liu
YXYong Xue
Yong Xue
CLChunhua Liu
Chunhua Liu
QLQiao-Ming Lou
Qiao-Ming Lou
JWJingfeng Wang
Jingfeng Wang
Yu-Ming WangYu-Ming Wang
Yu-Ming Wang
Background: Over the past two decades, a striking increase in the number of people with metabolic syndrome (MS) has taken place worldwide. With the elevated risk of not only diabetes but also cardiovascular morbidity and mortality, there is urgent need for strategies to prevent this emerging global epidemic. The present study was undertaken to investigate the effects of dietary eicosapentaenoic acid-enriched phospholipid (EPA-PL) on metabolic disorders. Methods: Male C57BL/6J mice (n = 7) were fed one of the following 4 diets for a period of 4 weeks: 1) a modified AIN-96G diet with 5% corn oil (control diet); 2) a high fat (20%, wt/wt) and high fructose (20%, wt/wt) diet (HF diet); 3) the HF diet containing 1% SOY-PL (SOY-PL diet); 4) the HF diet containing 1% EPA-PL (EPA-PL diet). The oral glucose tolerance test was performed. Plasma TG, TC, glucose, NEFA, insulin, leptin, adiponectin, TNF-α and IL-6 levels were assessed. In addition, hepatic lipid levels, lipogenic, and lipidolytic enzyme activities and gene expressions were evaluated. Results: Both EPA-PL and SOY-PL significantly inhibited body weight gain and white adipose tissue accumulation, alleviated glucose intolerance, and lowered both serum fasting glucose and NEFA levels substantially. Only EPA-PL significantly reduced serum TNF-α and IL-6 levels, and increased serum adiponectin level. EPA-PL was more effective in reducing hepatic and serum TG and TC levels than SOY-PL. Both EPA-PL and SOY-PL reduced the activities of hepatic lipogenic enzymes, such as FAS and G6PDH, but only EPA-PL significantly increased CPT, peroxisomal β-oxidation enzymes activities and CPT-1a mRNA level. Alterations of hepatic lipogenic gene expressions, such as FAS, G6PDH, ACC, SCD-1 and SREBP-1c were consistent with changes in related enzyme activities. Conclusions: According to our study, EPA-PL supplementation was efficacious in suppressing body fat accumulation, and alleviating insulin resistance and hepatic steatosis by modulating the secretion of adipocytokines and inflammatory cytokines, suppression of SREBP-1c mediated lipogenesis and enhancement of fatty acid β-oxidation. These results demonstrate that EPA-PL is a novel beneficial food component for the prevention and improvement of metabolic disorders.

Verified
Journal Article
Open access
PDF file
HDHuanghuang Dai
Huanghuang Dai
AOakira otsuka
akira otsuka
KTKurumi Tanabe
Kurumi Tanabe
TYTeruyoshi Yanaglta
Teruyoshi Yanaglta
JNJiro Nakayama
Jiro Nakayama
Hiroshi KitagakiHiroshi Kitagaki
Hiroshi Kitagaki
Glucosylceramide is present in many foods, such as crops and fermented foods. Most glucosylceramides are not degraded or absorbed in the small intestine and pass through the large intestine. Glucosylceramide exerts versatile effects on colon tumorigenesis, skin moisture, cholesterol metabolism and improvement of intestinal microbes in vivo. However, the mechanism of action has not yet been fully elucidated. To gain insight into the effect of glucosylceramide on intestinal microbes, glucosylceramide was anaerobically incubated with the dominant intestinal microbe, Blautia coccoides, and model intestinal microbes. The metabolites of the cultured broth supplemented with glucosylceramide were significantly different from those of broth not treated with glucosylceramide. The number of Gram-positive bacteria was significantly increased upon the addition of glucosylceramide compared to that in the control. Glucosylceramide endows intestinal microbes with tolerance to secondary bile acid. These results first demonstrated that glucosylceramide plays a role in the modification of intestinal microbes.

12 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SISayaka Iizasa
Sayaka Iizasa
KNKoji Nagao
Koji Nagao
KTKeisuke Tsuge
Keisuke Tsuge
Yukio NaganoYukio Nagano
Yukio Nagano
TYTeruyoshi Yanaglta
Teruyoshi Yanaglta
Hepatic steatosis is an early stage in the progression of non-alcoholic fatty liver disease (NAFLD) and can lead to the development of non-alcoholic steatohepatitis (NASH), a major cause of liver-related morbidity and mortality. Identification of dietary components that can alleviate hepatic steatosis is crucial for developing effective therapeutic strategies for NAFLD. Recently, we demonstrated the impact of lipids extracted from the marine red alga Susabinori (Pyropia yezoensis) in a murine model of type 2-diabete (db/db). We found that Susabinori lipids (SNL), abundant in eicosapentaenoic acid (EPA)-containing polar lipids, protected against obesity-induced hepatic steatosis in db/db mice. To understand the specific genes or biological pathways underlying the effects of SNL, we conducted RNA-Seq analysis of the hepatic transcriptome. By performing comparative analysis of differentially expressed genes between normal mice and db/db mice consuming a control diet, as well as SNL-fed db/db mice, we identified the 15 SNL-dependent up-regulated genes that were down-regulated in db/db mice but up-regulated by SNL feeding. Gene ontology and pathway analysis on these 15 genes demonstrated a significant association with the metabolisms of arachidonic acid (AA) and linoleic acid (LA). Furthermore, we observed alterations in the expression levels of monoacylglycerol lipase (Magl) and fatty acid-binding protein 4 (Fabp4) in the SNL-fed db/db mice, both of which are implicated in AA and LA metabolism. Additionally, the livers of SNL-fed db/db mice exhibited reduced levels of AA and LA, but a high accumulation of EPA. In conclusion, the SNL diet might affect the metabolisms of AA and LA, which contribute to the improvement of hepatic steatosis. Our findings provide insights into the molecular mechanisms underlying the beneficial effects of SNL.

15 June 2026 in Nutraceuticals
Verified
Journal Article
Open access
PDF file
Bungo ShirouchiBungo Shirouchi
Bungo Shirouchi
MOMai Okumura
Mai Okumura
シ岩シオリ 岩崎
シオリ 岩崎
SOShigeki Oogai
Shigeki Oogai
KYKaede Yamasaki
Kaede Yamasaki
TYTeruyoshi Yanaglta
Teruyoshi Yanaglta
The leaves and bark of Litsea species have traditionally been used as folk medicine to treat pain, headache, inflammation, diarrhea, and gastroenteritis. This study investigated whether dietary supplementation with Litsea cubeba leaves could preserve key functional components of the colonic barrier in a mouse model of dextran sulfate sodium (DSS)-induced ulcerative colitis. Male C57BL/6J mice were fed a control diet or a diet supplemented with L. cubeba leaves (20 g/kg diet) for 2 weeks, and colitis was induced by administering 3% (w/v) DSS in drinking water during the final week. Dietary L. cubeba leaf supplementation significantly attenuated DSS-induced body weight loss and suppressed the increase in Disease Activity Index. In addition, L. cubeba leaf supplementation attenuated DSS-induced reduction in fecal immunoglobulin A content and significantly prevented the reduction in fecal mucin content, which are key functional components of the colonic barrier. Furthermore, plasma levels of the inflammatory chemokine monocyte chemoattractant protein-1 were significantly decreased by L. cubeba leaf supplementation, accompanied by a reduction in plasma alanine aminotransferase activity, a marker of liver injury. These findings suggest that dietary L. cubeba leaf supplementation alleviates DSS-induced ulcerative colitis in mice, at least in part, by preserving key functional components of the colonic barrier rather than predominantly through direct suppression of colonic inflammatory gene expression.